ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовостиTraderScreen

KUROS BIOSCI.AG NAM.SF-,1/  CH0325814116  /

München
-  - Изменение - Объем сделки Бид- Предложение- Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
-EUR - 0
Оборот: 0.00		 -Величина цены спроса: - -Величина цены предложения: - 975.47 млнEUR - -
GlobeNewswire 03.02.2022 Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
GlobeNewswire 26.10.2021 Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales
GlobeNewswire 28.09.2021 Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting
GlobeNewswire 15.07.2021 Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royal...
GlobeNewswire 18.03.2021 Kuros Biosciences Reports Results for the Full Year 2020
GlobeNewswire 10.03.2021 Kuros Biosciences to Present at Upcoming Clinical and Investor Conferences
GlobeNewswire 02.03.2021 Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe
GlobeNewswire 09.09.2020 CORRECTING AND REPLACING -- Kuros Biosciences’s Licensee Checkmate Pharmaceuticals Completes its IPO...
GlobeNewswire 09.09.2020 Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
GlobeNewswire 01.09.2020 Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PT...
GlobeNewswire 12.08.2020 Kuros Biosciences Reports Results for First Half 2020
GlobeNewswire 22.07.2020 Kuros Biosciences Further Strengthens Orthobiologics Patent Portfolio
GlobeNewswire 26.03.2020 Kuros Biosciences Reports Results for the Full Year 2019
GlobeNewswire 18.03.2020 Kuros Strengthens Orthobiologics Patent Portfolio
GlobeNewswire 30.01.2020 Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading S...
GlobeNewswire 02.10.2019 Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advan...
GlobeNewswire 24.09.2019 Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North Americ...
GlobeNewswire 03.09.2019 Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Cli...
GlobeNewswire 20.08.2019 Kuros Biosciences Reports Results for First Half 2019
GlobeNewswire 09.07.2019 Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia...
GlobeNewswire 30.04.2019 Kuros Biosciences to Propose Re-Appointment of Chairman and Board Members at Annual General Meeting
GlobeNewswire 12.04.2019 Kuros Biosciences Reports Results for the Full Year 2018
GlobeNewswire 09.04.2019 Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million
GlobeNewswire 13.03.2019 Kuros Biosciences Receives US Marketing Clearance for Intervertebral Body Fusion Device
GlobeNewswire 11.02.2019 Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuros’s Advanced ...